Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.

@article{Kratz2001DevelopmentAI,
  title={Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.},
  author={Felix Kratz and Joachim Drevs and Guifang Bing and Cornelia Stockmar and Karen Scheuermann and Prettina Lazar and Catharina Unger},
  journal={Bioorganic & medicinal chemistry letters},
  year={2001},
  volume={11 15},
  pages={2001-6}
}
Two doxorubicin albumin conjugates (A-DP1 and A-DP2), which differ in their substrate specificity for the matrix metalloproteinases MMP2 and MMP9, were prepared by binding maleimide doxorubicin peptide derivatives to the cysteine-34 position of human serum albumin. The incorporated octapeptide, Gly-Pro-Gln-Arg-Ile-Ala-Gly-Gln, in A-DP2 is not cleaved by activated MMP2 and MMP9 in contrast to Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln incorporated in A-DP1 that is cleaved efficiently by activated MMP2 and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.

German patent application

  • F. Kratz
  • DE A19926475.9,
  • 1999

Similar Papers

Loading similar papers…